INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58601, 21070, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58602, 27421, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58603, 28046, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58604, 959, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58605, 6667, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58606, 6669, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58607, 6670, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58608, 6674, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58609, 6675, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58610, 6676, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58611, 6678, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58612, 10830, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58613, 14419, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58614, 19475, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58615, 19476, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58616, 21063, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58617, 21065, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58618, 21067, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58619, 21070, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58620, 27421, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58621, 28046, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58622, 959, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58623, 6667, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58624, 6669, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58625, 6670, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58626, 6674, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58627, 6675, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58628, 6676, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58629, 6678, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58630, 10830, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58631, 14419, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58632, 19475, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58633, 19476, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58634, 21063, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58635, 21065, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58636, 21067, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58637, 21070, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58638, 27421, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58639, 28046, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58640, 3926, 'Isoxsuprine', 'Hemorrhage', 'The use of isoxsuprine is contraindicated in patients with arterial bleeding.  The alpha adrenoreceptor antagonism of isoxsuprine produces vasodilation that may exacerbate arterial bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58641, 29016, 'Isoxsuprine', 'Hemorrhage', 'The use of isoxsuprine is contraindicated in patients with arterial bleeding.  The alpha adrenoreceptor antagonism of isoxsuprine produces vasodilation that may exacerbate arterial bleeding.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58642, 0, 'Istradefylline', 'Liver Failure', 'Istradefylline has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), and its use should be avoided in these patients.  In patients with moderate hepatic impairment (Child-Pugh B), the steady-state exposures were predicted to be 3.3-fold higher.  Therefore, the maximum recommended dosage of istradefylline in patients with moderate hepatic impairment (Child-Pugh B) is 20 mg once daily.  Patients should be closely monitored for adverse events when receiving treatment.  No dose adjustment is needed in patients with mild hepatic impairment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58643, 0, 'Istradefylline', 'Kidney Failure, Chronic', 'Istradefylline has not been evaluated in patients with end-stage renal disease (ESRD) (CrCl <15 mL/min) or ESRD requiring hemodialysis.  Caution is advised if prescribed in these patients.  No dosage adjustment is needed in patients with mild, moderate or severe renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58644, 0, 'Istradefylline', 'Psychotic Disorders', 'Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with istradefylline.  Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking this drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58645, 2053, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58646, 3639, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58647, 3707, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58648, 3708, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58649, 3709, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58650, 3984, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58651, 6608, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58652, 14162, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58653, 15837, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58654, 15838, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58655, 16808, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58656, 21002, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58657, 21007, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58658, 21008, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58659, 21031, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58660, 30354, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58661, 2053, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58662, 3639, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58663, 3707, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58664, 3708, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58665, 3709, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58666, 3984, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58667, 6608, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58668, 14162, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58669, 15837, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58670, 15838, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58671, 16808, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58672, 21002, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58673, 21007, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58674, 21008, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58675, 21031, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58676, 30354, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58677, 2053, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58678, 3639, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58679, 3707, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58680, 3708, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58681, 3709, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58682, 3984, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58683, 6608, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58684, 14162, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58685, 15837, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58686, 15838, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58687, 16808, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58688, 21002, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58689, 21007, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58690, 21008, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58691, 21031, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58692, 30354, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58693, 2053, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58694, 3639, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58695, 3707, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58696, 3708, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58697, 3709, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58698, 3984, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58699, 6608, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58700, 14162, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', '', 'DDInter', 0);
